Benzinga | Jan 24, 2022 09:05AM EST

B. Riley Securities Maintains Buy on IN8bio, Lowers Price Target to $9

B. Riley Securities analyst Kalpit Patel maintains IN8bio (NASDAQ:INAB) with a Buy and lowers the price target from $19 to $9.